• Liver biopsy remains the only diagnostic tool to stage NAFLD and to assess disease progression; clinical/biochemical parameters may be used as surrogate markers, but their accuracy is limited • The presence of multiple features of the metabolic syndrome is associated with more advanced and more progressive disease • Obesity and diabetes are associated with more aggressive liver disease, but their effect on final outcome is uncertain • Cardiovascular risk may compete with liver disease-related risk in dictating the final outcome • Longitudinal studies based on liver biopsy data are needed to define the natural history of disease

NAFLD: a critical appraisal by the clinician

MARCHESINI REGGIANI, GIULIO;MARZOCCHI, REBECCA
2007

Abstract

• Liver biopsy remains the only diagnostic tool to stage NAFLD and to assess disease progression; clinical/biochemical parameters may be used as surrogate markers, but their accuracy is limited • The presence of multiple features of the metabolic syndrome is associated with more advanced and more progressive disease • Obesity and diabetes are associated with more aggressive liver disease, but their effect on final outcome is uncertain • Cardiovascular risk may compete with liver disease-related risk in dictating the final outcome • Longitudinal studies based on liver biopsy data are needed to define the natural history of disease
The Microscope at the Bedside
10
15
G. Marchesini Reggiani; R. Marzocchi
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/52956
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact